Korea Investment CORP Has $50.72 Million Stock Position in Elevance Health, Inc. $ELV

Korea Investment CORP lessened its holdings in Elevance Health, Inc. (NYSE:ELV) by 9.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,982 shares of the company’s stock after selling 16,113 shares during the period. Korea Investment CORP owned about 0.07% of Elevance Health worth $50,724,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in ELV. Norges Bank acquired a new position in Elevance Health during the 2nd quarter valued at about $1,148,379,000. Sanders Capital LLC raised its stake in shares of Elevance Health by 24.7% in the second quarter. Sanders Capital LLC now owns 5,825,208 shares of the company’s stock worth $2,265,773,000 after purchasing an additional 1,152,440 shares during the last quarter. Artisan Partners Limited Partnership lifted its holdings in shares of Elevance Health by 24.5% in the third quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock valued at $1,478,857,000 after purchasing an additional 901,626 shares in the last quarter. First Eagle Investment Management LLC boosted its position in shares of Elevance Health by 25.0% during the third quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock valued at $1,292,029,000 after buying an additional 798,457 shares during the last quarter. Finally, Beutel Goodman & Co Ltd. purchased a new position in shares of Elevance Health during the second quarter valued at approximately $293,141,000. Institutional investors own 89.24% of the company’s stock.

Elevance Health Stock Up 1.1%

Elevance Health stock opened at $289.56 on Monday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $458.75. The firm has a 50 day moving average price of $344.64 and a 200-day moving average price of $335.34. The company has a market capitalization of $63.91 billion, a P/E ratio of 11.53, a P/E/G ratio of 1.60 and a beta of 0.51. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.10 by $0.23. The company had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. Elevance Health’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same quarter last year, the business posted $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 25th. Shareholders of record on Tuesday, March 10th will be given a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is 27.23%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $332.00 price target on shares of Elevance Health in a research report on Thursday, January 29th. UBS Group set a $400.00 price objective on shares of Elevance Health in a report on Thursday, January 29th. Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Royal Bank Of Canada downgraded shares of Elevance Health from an “outperform” rating to a “sector perform” rating and set a $358.00 target price for the company. in a report on Tuesday, February 3rd. Finally, Wall Street Zen lowered shares of Elevance Health from a “buy” rating to a “hold” rating in a research report on Sunday, February 8th. Twelve equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $390.55.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.